Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine  by Sundararajan, Aarthi et al.
R
b
n
A
W
J
a
6
b
c
d
e
f
g
R
a
A
R
R
A
A
K
N
V
B
M
A
I
h
0Vaccine 33 (2015) 568–576
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
obust  mucosal-homing  antibody-secreting  B  cell  responses  induced
y  intramuscular  administration  of  adjuvanted  bivalent  human
orovirus-like  particle  vaccine
arthi  Sundararajana,1, Mark  Y.  Sangstera, Sharon  Freyb, Robert  L.  Atmarc,
ilbur  H.  Chend,  Jennifer  Ferreirae, Robert  Bargatze f, Paul  M.  Mendelmanf,
ohn  J.  Treanorg,∗∗, David  J.  Tophama,∗
Center for Vaccine Biology & Immunology, Department of Microbiology & Immunology, University of Rochester School of Medicine and Dentistry,
01  Elmwood Avenue, Box 609, Rochester, NY 14642, USA
Saint Louis University, School of Medicine, 1402 South Grand Boulevard, St. Louis, MO 63104, USA
Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Center for Vaccine Development, The University of Maryland Medical School, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA
The EMMES Corporation, 401 North Washington Street, Suite 700, Rockville, MD 20850, USA
Takeda Vaccines (Montana), Inc., 2155 Analysis Drive, Bozeman, MT 59718, USA
Division of Infectious Disease, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 689,
ochester, NY 14642, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 16 June 2014
eceived in revised form 29 August 2014
ccepted 15 September 2014
vailable online 22 November 2014
eywords:
orovirus
accine
 cell
ucosal
ntibody
a  b  s  t  r  a  c  t
Background:  Two  major  antigenically  heterogenous  norovirus  genogroups  (GI  and  GII) commonly  infect
humans  and  are the leading  cause  of  foodborne,  viral  gastrointestinal  infections  in adults.
Methods:  We assessed  B  cell  responses  in  participants  in  a double-blind,  placebo-controlled,  dose-
escalation  phase  1 study  of the  safety  and  immunogenicity  of an intramuscular  bivalent  norovirus
virus-like  particle  (VLP)  vaccine.  The  vaccine  contained  a GI.1  VLP  (Norwalk)  and a consensus  GII.4  VLP,
representing  the two major  genotypes  that  cause  human  disease,  and  was  administered  on  days  0 and
28 to  healthy  adults  aged  18–49  years.  Four  separate  cohorts  received  increasing  doses  of 5 g,  15  g,
50  g, and 150  g of each  VLP  adjuvanted  in monophosphoryl  lipid  A and alum.  PBMCs  were analyzed
for  B cell  activation  and  mucosal  homing  markers  (ﬂow  cytometry)  and  VLP-speciﬁc  and  total  IgG  and
IgA  Ab-secreting  cells  (ASCs);  and  serum  titers  of  VLP-speciﬁc  IgG, IgA, and  Pan-Ig  were determined.
Results:  The  vaccine  elicited  CD27+  CD38+  plasmablasts  and  high  frequencies  of  ASCs  speciﬁc  for  both
VLP antigens  in the  peripheral  blood  at 7  days  after  the ﬁrst  dose.  The  plasmablasts  exhibited  a mucosal-
homing  phenotype  and  included  a high  proportion  of IgA  ASCs.  Serum  antibodies  increased  as early  as 7
days  after  the  ﬁrst immunization.
Conclusions:  The  data  suggest  that  a single  dose  of  the  IM bivalent  norovirus  vaccine  is effective  in activat-
ing pre-existing  B  cell  memory.  The  rapid  B  cell  response  and  the  mucosal  homing  phenotype  of  induced
ASCs  are  consistent  with  anamnestic  responses  in subjects  primed  by prior  oral  norovirus  infection.
This study  is registered  at ClinicalTrials.gov  Identiﬁer  NCT01609257.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND∗ Corresponding author. Tel.: +1 585 273 1400.
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1. Introduction
Noroviruses are estimated to cause more than 50% of viral gas-
troenteritis cases worldwide [1,2] and in excess of 21 million cases
of acute gastroenteritis annually in the United States [3,4]. Trans-
mission is via the fecal-oral route and outbreaks commonly result
from contaminated food [5,6]. The low infectious dose and high
level of environmental stability contribute to rapid viral spread in
populations housed in close quarters [3,6,7].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
Demographics and baseline characteristics by treatment group for subjects at the University of Rochester with fresh PBMC Data Cohort A, dosage escalation.
VLP Vaccine dose (prime/boost, g) 5/5
(N = 5)
15/15
(N = 4)
50/50
(N = 4)
150/150
(N = 4)
Placebo
(N = 3)
All subjects
(N = 20)
Gender – n (%)
Male 3 (60.0) 2 (50.0) 0 1 (25.0) 1 (33.3) 7 (35.0)
Female  2 (40.0) 2 (50.0) 4 (100.0) 3 (75.0) 2 (66.7) 13 (65.0)
Ethnicity – n (%)
Non-Hispanic 3 (60.0) 4 (100.0) 4 (100.0) 4 (100.0) 3 (100.0) 18 (90.0)
Hispanic 2 (40.0) 0 0 0 0 2 (10.0)
Race  – n (%)
American Indian/Alaskan Native 0 0 0 0 0 0
Asian  0 0 1 (25.0) 1 (25.0) 0 2 (10.0)
Hawaiian/Paciﬁc Islander 0 0 0 0 0 0
Black/African American 1 (20.0) 1 (25.0) 1 (25.0) 0 1 (33.3) 4 (20.0)
White  4 (80.0) 2 (50.0) 2 (50.0) 3 (75.0) 2 (66.7) 13 (65.0)
Multi-Racial 0 1 (25.0) 0 0 0 1 (5.0)
Other/unknown 0 0 0 0 0 0
Age
Mean  (STD) 30.2 (5.5) 33.0 (10.2) 35.8 (6.8) 36.0 (12.1) 24.0 (2.6) 32.1 (8.5)
Median 30.0 34.5 37.5 36.0 23.0 30.0
Min,  Max  (23, 37) (20, 43) (26, 42) (23, 49) (22, 27) (20, 49)
Saliva  secretor status – n (%)
Positive 3 (60.0) 2 (50.0) 1 (25.0) 4 (100.0) 3 (100.0) 13 (65.0)
Negative 2 (40.0) 2 (50.0) 3 (75.0) 0 0 7 (35.0)
Blood  type – n (%)
A 2 (40.0) 2 (50.0) 2 (50.0) 3 (75.0) 0 9 (45.0)
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VLPs, MPL  and aluminum hydroxide as adjuvants, sodium chlo-
ride and l-histidine as buffer (pH 6.3–6.7), ethanol, and water for
injection (Table 2).
Table 2
Composition of four IM norovirus bivalent VLP vaccine formulations per 0.5 mL.
Total VLP per
dose (g)
GI.1-VLP (g) GII.4 VLP (g) MPL  (g) Ala (mg)
10 5 5 50 0.5
30 15 15 50 0.5O  3 (60.0) 2 (50.0)
AB  0 0 
Noroviruses are classiﬁed into ﬁve genogroups on the basis of
hylogenetic analysis of the major viral capsid protein, VP1 [5].
iruses in the GI and GII genogroups cause most human disease,
ith GII genogroup viruses predominating worldwide since the
990s [5,8]. The genogroups are further divided into genotypes;
he prototypic Norwalk virus forms the GI.1 genotype, and the
II.4 genotype represents the predominant currently circulating
oroviruses.
The ﬁnding that expressed recombinant norovirus VP1 self-
ssembles into virus-like particles (VLPs) has stimulated the
evelopment of norovirus vaccine candidates [5]. Each VLP con-
ists of 90 VP1 dimers and is structurally and immunogenically
imilar to the intact norovirus particle [8–12]. Norovirus vaccine
andidates based on VLPs have been tested in a number of clin-
cal trials [8,9,13,14]. Oral and intranasal routes of administration
ave been employed with the objective of inducing mucosal immu-
ity to optimally combat natural norovirus infection [8,9,13–16].
orovirus VLP vaccines elicit both T and B cell immunity, as found
or other VLP-based vaccines such as the licensed human papil-
omavirus vaccines [11,17–25]. Norovirus vaccine studies to date
ave mostly focused on a single genogroup, although multivalent
accines covering more than one genogroup may  generate broader
rotection.
Although norovirus VLP vaccines alone are immunogenic, the
ncorporation of appropriate adjuvants is likely to enhance immune
esponses and improve protection. This may  be particularly impor-
ant when targeting age groups that tend to respond poorly to
accination. Monophosphoryl lipid A (MPL) and aluminum hydrox-
de (alum) are two adjuvants approved for use in human vaccines.
PL, a lipopolysaccharide derivative from Salmonella minnesota
595 [26,27], is immunostimulatory because of toll-like receptor-4
gonist activity [27] and is licensed for use in a human papillo-
avirus vaccine.
The norovirus vaccine used in our study consisted of VLPs from
nsect cell-derived, recombinant VP1 proteins representing the GI.I
nd GII.4 genogroups, together with the adjuvants MPL  and alum.
 phase I clinical trial of the adjuvanted, bivalent norovirus VLP
accine given intramuscularly (IM) was conducted to assess safety
nd to measure the seroresponse to escalating doses of a two-dose (50.0) 1 (25.0) 2 (66.7) 10 (50.0)
 0 1 (33.3) 1 (5.0)
regimen. Here, we present an analysis of the circulating antibody-
secreting cell (ASC) response to the vaccine in a subset of trial
participants.
2. Methods
2.1. Study Design and Subjects
A total of 20 healthy subjects 18 to 49 years of age were enrolled
sequentially into each of four dose groups of 4–5 subjects (Table 1).
Dose groups received two  IM administrations (days 0 and 28) of
a bivalent norovirus VLP vaccine containing 5 g, 15 g, 50 g,
or 150 g of each VLP component (GI.1 and GII.4). Subjects were
randomized 5:1 to receive vaccine or saline control (placebo). All
subjects were tested for saliva secretor status and blood type prior
to the trial. After all being informed of the nature and possible
consequences of the study, subjects were enrolled under informed
consent using a protocol reviewed and approved by the University
of Rochester Research Subjects Review Board.
2.2. Vaccine and placebo
The norovirus bivalent VLP vaccine contained GI.1 and GII.4100 50 50 50 0.5
300 150 150 50 0.5
a As aluminum hydroxide. Placebo formulation consisted of sterile normal saline
for  injection (0.9% NaCl and preservative-free).
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Table 3
Flow cytometry markers and ﬂuorochromes used for assessing B cell phenotypes
and  homing potential.
Marker Clone Fluorochrome
Forward scatter – FSC
Side scatter – SSC
47  FIB504 FITC
CD138 MI  15 APC
Live/dead – Alexa 430
CCR10 6588-5 PE
CD19 J3-119 PE-Texas Red
CD27 1A4CD27 PE-Cy5
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CD38 HIT2 PE-Cy7
CD62L Dreg-56 APC-Alexa 750
.3. Immune assays
.3.1. B cell enrichment and phenotyping
B cells were enriched from peripheral blood mononuclear cells
PBMCs) by negative selection [28], resulting in CD19+ B cell
urities from 65 to 95%. B cell phenotyping by ﬂow cytometry
nvolved staining aliquots of PBMCs before and after enrichment
ith a 10 or 11-color panel of stains (Table 3). Data on stained cells
as collected on a Becton-Dickinson LSR-II ﬂow cytometer using
iva software and analyzed using FlowJo (TreeStar).
.3.2. Enzyme-Linked ImmunoSpot assay (ELISpot) assay for ASCs
Vaccine-speciﬁc and total IgG and IgA ASCs were enumerated by
LISpot assay (20). Brieﬂy, 96-well IP ﬁlter plates (Millipore, Biller-
ca, MA)  were coated overnight at 4 ◦C with antigens or Ig capture
ntibodies. For detection of VLP-speciﬁc ASCs, wells were coated
ith 1 g/ml × 100 l/well GI.1 Norwalk VLP (EN544-01-10-001,
akeda Vaccines Inc., Bozeman, MT), or GII.4 VLP (EN544-01-10-
01A Takeda Vaccines Inc.). For total IgG or IgA ASCs, wells were
oated with 4 g/ml × 100 l/well goat-anti human IgM + IgA + IgG
ntibody (KPL, Gaithersburg, MD). Control wells were plated with
BS or with recombinant inﬂuenza H3 Wisconsin/67/05 HA pro-
ein (BEIR) diluted in PBS to 1 g/ml × 40 l/well. Enriched B cells
ere resuspended in complete medium containing either alka-
ine phosphatase-conjugated goat anti-human IgG (H + L) (KPL) at
.2 g/ml or alkaline phosphatase-conjugated goat anti-human IgA
KPL) at 0.2 g/ml for the detection of IgG or IgA ASCs, respectively.
erial dilutions of the cells were prepared in the coated/blocked
lates and the plates were incubated for at least 4 h at 37 ◦C in 5%
O2. Spots representing IgG or IgA ASCs were developed with a
ector Blue alkaline phosphatase substrate kit (Vector Laborato-
ies, Burlingame, CA) and counted using a CTL ImmunoSpot plate
eader and counting software (Cellular Technology Limited, Cleve-
and, OH).
.3.3. Serology
For the Rochester cohort, blood samples were collected before
he ﬁrst vaccination (day 0) and on days 7, 28, and 35 after the
rst dose of vaccine for evaluation of serum antibodies. Titers of
orovirus-speciﬁc Ig (Pan-Ig) and class-speciﬁc (IgG and IgA) anti-
odies were determined by enzyme linked immunoassay (ELISA)
nd duplex, time-resolved, dissociation-enhanced lanthanide ﬂuo-
escence immunoassay (DELFIA), respectively [9,10].
.4. Statistical analyses
Data was analyzed using SAS version 9.3. A regression was per-
ormed to test for serological differences between dose groups.
or this analysis, the log serological response was  modeled with
reatment group, according to dosage (0, 5, 15, 50, or 150 g), the
og baseline serological result and their interaction as covariates.ne 33 (2015) 568–576
Additionally, each subject’s serological log fold rise from base-
line was calculated and a student’s t-test was used to evaluate
any treatment effect, for all vaccine subjects collectively. Negative
serological results were analyzed as half the lower limit of quantiﬁ-
cation (LLOQ), deﬁned as the lowest amount of antibody in a sample
that could be quantitatively determined. Differences between the
dose groups for expression of B cell phenotype and homing markers
were tested by regression analysis. Correlations between the fre-
quencies of B cells with a plasmablast phenotype and frequencies
of VLP-speciﬁc ASCs were determined by calculating Spearman’s
correlation coefﬁcients and P values with a two-tailed test.
3. Results
3.1. Serology
In this report, we  analyzed a local cohort of 20 subjects aged
18–49 years from a larger, multicenter cohort that included sub-
jects aged 50–64 and 65–83 years. The older subject groups were
not part of our analysis. Post hoc analysis revealed that each dose
group contained 3–5 subjects and included a total of three placebo
controls. Serum antibody responses to the GI.1 antigens were
higher than to the GII.4 antigens, as observed in the larger cohort.
When results from all dose groups were collated by time point,
there were signiﬁcant increases in GI.1 and GII.4 VLP-speciﬁc IgG,
IgA and Pan-Ig serum antibody levels at days 7, 28, and 35 compared
to the prevaccination (day 0) titers (Fig. 1). There was no evidence
of a boost in serum titers after the second vaccine administration
on day 28. VLP-speciﬁc antibody titers did not change in recipients
of the placebo.
3.2. Antibody-secreting cell analysis
The robust serological responses indicated substantial ASC for-
mation. To assess the magnitude and speciﬁcity of the ASC response
in peripheral blood, an ELISpot assay was  used to determine GI.1
and GII.4 VLP-speciﬁc and total IgG and IgA ASC frequencies. All sub-
jects that received bivalent norovirus VLP vaccine demonstrated
high ASC frequencies in the peripheral blood on day 7 after the ﬁrst
vaccination (Fig. 2). After the study was  unblinded, the three sub-
jects among the dose groups that had undetectable VLP-speciﬁc
ASC responses were revealed to be placebo (P) recipients. The
response after the ﬁrst vaccination tended to be biased toward
IgA ASCs (Fig. 2A, B, and E). In general, ASCs speciﬁc for GI.1 VLP
antigen predominated when both IgA and IgG ASCs were viewed
collectively (Fig. 2E). However, the group that received the 150 g
dose exhibited a higher proportion of GII.4 VLP-speciﬁc ASCs com-
pared to the lower dose groups (49% vs. ∼30%; Fig. 2E). Interestingly,
the VLP-speciﬁc ASC responses on day 7 were much greater in
magnitude (frequency per million CD19+ cells) than we  had typ-
ically observed after inﬂuenza vaccination [28,29]. The strong IgA
ASC bias is consistent with a mucosal (versus systemic) immune
response, yet did not lead to a similar bias in serum immunoglob-
ulin (Fig. 1 and [30]). There were no apparent increases in ASC
frequencies corresponding to higher VLP doses.
Subjects (13 out of 20) who returned on day 28 for the second
vaccination were analyzed by ELISpot assay for VLP-speciﬁc and
total ASC after 7 days (day 35). The frequencies of GI.1 and GII.4
VLP-speciﬁc ASCs were two  orders of magnitude lower than the
responses measured on day 7 after the ﬁrst vaccination (Fig. 2C and
D). The IgA bias was  diminished and, interestingly, ASC frequen-
cies were somewhat higher in the 5 g (lowest) dose group than
in the other groups. There was  a signiﬁcant (p = 0.0111) negative
correlation between the GI.1-speciﬁc ASC frequency on day 7 with
that on day 35, suggesting that a strong response to the ﬁrst dose
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Fig. 1. Serum titers of norovirus GI.1- and GII.4-speciﬁc IgA, IgG, and Pan-Ig antibodies. (A) IgA titer against GI.1; (B) IgA titer against GII.4; (C) IgG titer against GI.1; (D) IgG
titer  against GII.4; (E) Pan-Ig titer against GI.1; (F) Pan-Ig titer against GII.4. Subjects were immunized IM with an adjuvanted bivalent norovirus VLP vaccine on days 0 and
28.  Serum was  collected on days 0, 7, 28, and 35 relative to the ﬁrst immunization. Norovirus GI.1 and GII.4 VLP-speciﬁc antibodies titers were determined by DELFIA (IgA
and  IgG) and ELISA (Pan-Ig). Data points represent titers for individual subjects. Data from all dose groups were combined by day of blood draw before plotting and analysis.
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bach  subject’s serological log fold rise from day 0 was  calculated and a student’s t-t
or  placebo recipients are combined from all sampling days. Horizontal bars show th
dentiﬁed by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001).
nhibited the response to the second dose. The day 7 versus day 35
orrelations were not signiﬁcant for the GII.4 VLP or total IgG and
gA. Overall, ASC measurements were consistent with the serum
b analysis and demonstrate a rapid and vigorous B cell response
o the ﬁrst vaccination, but little if any boosting effect of the sec-
nd vaccination, a pattern suggesting activation of pre-existing,
accine-speciﬁc memory B cells by the ﬁrst vaccination.
.3. Flow cytometric analysis of B cells in the peripheral bloodOne sample collected after the ﬁrst vaccination was lost during
rocessing, leaving 19 samples for ﬂow cytometric analysis. B cells
deﬁned as CD3− CD19+ cells) were analyzed by ﬂow cytometry
efore and after enrichment from PBMCs; dead cells and doubletsas used to evaluate any treatment effect, for all vaccine subjects collectively. Titers
metric mean titer and 95% conﬁdence interval. P values relative to day 0 results are
were excluded (Fig. 3A and B). B cells transitioning into antibody-
secreting plasmablasts express CD27 and CD38 [28,31] and those
actively secreting antibodies are enriched among the CD138+ sub-
set [32]. On day 7 after the ﬁrst vaccination, a robust population
of CD27+ CD38+ B cells was  detected in most vaccine recipients,
but not in placebo (0 g dose) controls (Fig. 3C and G), indicat-
ing a strong B cell response to the vaccine. The potential to home
to peripheral lymphoid tissues or to mucosal tissues such as the
gut was assessed by measuring expression of the integrin chain
7, the chemokine receptor CCR10+, and the lymph node homing
receptor CD62L (l-selectin). A comparison of differentiation and
mucosal homing markers on CD27+ CD38+ and CD27− CD38− B
cells demonstrated upregulation of CD138 (Fig. 3D and H) and par-
ticularly 7 (Fig. 3E and I) and CCR10 (Fig. 3F) on the CD27+ CD38+
572 A. Sundararajan et al. / Vaccine 33 (2015) 568–576
Fig. 2. Analysis of circulating GI.1 and GII.4 VLP-speciﬁc and total ASCs. Subjects were immunized twice (day 0 and day 28) with 5 g, 15 g, 50 g, or 150 g doses of an IM
adjuvanted bivalent norovirus vaccine. B cells enriched from PBMCs collected on day 7 and day 35 (day 7 after the second vaccination) were analyzed by ELISpot assay for
VLP-speciﬁc and total ASCs. (A and C) GI.1 VLP-speciﬁc IgA (black columns) and IgG (white columns) ASCs on day 7 (A) and day 35 (C). (B and D) GII.4 VLP-speciﬁc IgA (gray
columns) and IgG (striped columns) ASCs on day 7 (B) and day 35 (D). Only placebo (“P” on the x-axis) recipients (distributed among dose groups) had no VLP-speciﬁc ASCs
detected (shown as ND, none detected). Asterisks indicate that no PBMC sample was  available for analysis because subjects did not return for the day 35 sampling. (E) The
proportions of VLP-speciﬁc IgA and IgG ASCs in each dose group. For each dose group, ASCs of each VLP speciﬁcity and Ig class were summed and are shown as a percentage
of  the sum of all VLP-speciﬁc IgA and IgG ASCs. Pie chart shading corresponds to the shading in (A–D). (F and H) Total IgA (black columns) and IgG (white columns) on day 7
(F)  and day 35 (H) in each dose group. As negative controls, ASCs were measured in wells coated with inﬂuenza H3 rHA or PBS (for non-speciﬁc binding). Results on day 7
(G)  and day 35 (I) are shown for each dose group (gray columns = H3-speciﬁc IgA ASCs; striped columns = H3-speciﬁc IgG ASCs; black columns = non-speciﬁc IgA ASCs; white
columns = non-speciﬁc IgG ASCs).
A. Sundararajan et al. / Vaccine 33 (2015) 568–576 573
Fig. 3. Flow cytometric analysis of circulating B cells for plasmablast and homing markers. B cells were enriched from PBMCs collected on day 7 after IM vaccination with an
adjuvanted bivalent norovirus vaccine and analyzed by ﬂow cytometry. Representative staining is shown for CD3 and CD19 before (A) and after (B) B cell (CD19+) enrichment,
and  for CD27 and CD38 (C) after gating on the CD3− CD19+ population in the lower right quadrant in (B). The CD27+ CD38+ population (shaded histograms) was compared
with  the CD27− CD38− population (open histograms) to determine the expression of CD138 (D), 7 (E), and CCR10 (F) (panels show representative results). The proportion
of  CD19+ cells that were CD27+ CD38+ (G), CD27+ CD38+ CD138+ (H), and CD27+ CD38+ 7+ (I) are plotted for individual subjects in each dose group (dose = 0 g for placebo
recipients). (J) Representative staining of CCR10 and 7 among the CD27+ CD38+ (black dots) and CD27− CD38− (gray dots) cells. The proportions of CD19+ CD27+ CD38+
7+  cells that were CD62L− (K) or CD62L+ (L) are plotted for individual subjects in each dose group (dose = 0 g for placebo recipients).
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ells. The mucosal homing phenotype of the CD27+ CD38+ com-
ared to CD27− CD38− B cells was most obvious when looking
t dual expression of 7 and CCR10 (Fig. 3J). There was  a signiﬁ-
ant (p < 0.0001) trend toward higher proportions of CD27+ CD38+
ells that expressed 7 cells as the VLP dose increased (Fig. 3I). In
ddition, there was a signiﬁcant difference (p = 0.0013) between the
 g and 150 g dose groups in the proportion of CD27+ CD38+ 7+
ells. The proportion of CD27+ CD38+ cells that expressed CCR10
as consistently 97–99% (Fig. 3F).
Expression of CD62L is associated with preferential homing to
ymphoid tissues rather than peripheral tissues [33]. A higher pro-
ortion of CD27+ CD38+ 7+ cells were CD62L− (Fig. 3K and L).
verall, the expression proﬁles of CCR10, 7 integrin, and CD62L
n circulating CD27+ CD38+ cells on day 7 after vaccination are
onsistent with a bias toward mucosal homing. Flow cytometric
nalysis of B cells on days 28 and 35 (day 7 after the second vacci-
ation) showed no difference between pre and post immunization
n vaccine recipients, or from placebo controls (not shown), consis-
ent with our other data indicating a minimal B cell response to the
econd vaccination. For comparison, in a separate study of adults
eceiving trivalent inactivated seasonal inﬂuenza vaccine, the pro-
ortion of CD27+ CD38+ B cells (7.5%) was lower after the inﬂuenza
accine than after the norovirus vaccine in the current study, but
he proportions of CD27+ CD38+ cells that expressed CD138 (22.6%)
ere similar. The proportion of CD27+ CD38+ cells expressing 7
as lower after the inﬂuenza vaccine (29.5%), with more CD62L−
ells among the 7+ cells (79.5%), suggesting a peripheral hom-
ng pattern. Thus, compared to unadjuvanted inﬂuenza vaccine,
he adjuvanted bivalent norovirus vaccine elicited a more robust
lasmablast response and a mucosal homing phenotype among
lasmablasts.
. Discussion
This study provides the ﬁrst analysis of cellular aspects of the
umoral response to an experimental bivalent norovirus vaccine
o be tested in healthy adults. As reported [30], the vaccine elicited
trong serological responses to both VLP antigens and our analysis
f circulating ASCs on day 7 after the ﬁrst vaccination demonstrated
apid and vigorous formation of GI.1- and GII.4-speciﬁc ASCs. There
as a marked predominance of IgA over IgG ASCs in both the GI.1-
nd GII.4-speciﬁc responses. Notably, the serum antibody response
30] and the ASC response were stronger than in previous stud-
es of norovirus VLP vaccines [8,9,13,14]. Similar adjuvants were
sed in the different studies, so the key difference is the route of
mmunization. The IM route ensures that the entire dose of antigen
as the potential to stimulate the immune system, whereas only a
mall proportion of antigen given intranasally or orally is likely to
e taken up and delivered to immune inductive sites. Similarly, the
M route may  be more effective because the depot antigen prolongs
timulation of the immune system.
The rapid and vigorous ASC response to the ﬁrst vaccination
ndicates a recall response by memory B cells (MBCs), rather than
 response resulting from the activation of naïve B cells. Approxi-
ately 90% of adults carry norovirus-speciﬁc antibodies, indicating
ast exposure to circulating noroviruses. Most subjects in our study
robably generated a strongly IgA-biased norovirus-speciﬁc MBC
esponse following mucosal norovirus infection. This is likely to
xplain the large IgA ASC component in the response to IM vaccina-
ion. Group I noroviruses caused the majority of human infections
rior to 2001, when the GII serotypes began to circulate more
idely [5,34]. Currently circulating noroviruses continue to be of
he GII lineage, leading to the prediction that more recent exposures
o circulating virus would drive a dominant GII response. This is not
hat we observed, and there is no reason to believe the GI.1 VLP isne 33 (2015) 568–576
more or less immunogenic or antigenic than the GII.4 VLP. Instead
the B cell responses recalled by the vaccine may reﬂect early prim-
ing by the GI viruses that were more common prior to 2001 when
most of our 18–49 year-old subjects were likely to have been ﬁrst
exposed to the virus. We  saw evidence for more equal frequen-
cies of GI.1- and GII.4-speciﬁc ASCs at a high vaccine dose (150 g),
suggesting that a greater amount of antigen may  in part counter
differences in the frequencies of speciﬁc MBCs.
B and T cells activated by mucosal antigen exposure express
sets of homing molecules that promote localization in mucosal
tissues. In a study of an adjuvanted norovirus VLP vaccine given
intranasally, El-Kamary and colleagues [13] investigated homing
molecule expression by VLP-speciﬁc ASCs. CD19+ CD27+ ASCs
were sorted based on expression of CD62L and 7 prior to VLP-
speciﬁc ELISpot assay. Essentially, all VLP-speciﬁc IgG and IgA ASCs
expressed 7; all of the IgG ASCs and a proportion of the IgA
ASCs also expressed CD62L. Interestingly, in the present study
the expression of CD62L was  mixed among the CD27+ CD38+ and
CD27–CD38–B cell (CD19+) subsets, though we  did not distinguish
Ig isotype. In our analysis on day 7 after the ﬁrst vaccination, there
was a positive correlation between dose and the percent of CD19+
CD27+ CD38+ ASCs that expressed 7. Greater than 98% of ASCs
also expressed CCR10, a chemokine receptor that has a broad role
in mucosal homing. Collectively, our analysis indicates that IM
norovirus vaccination of adults generates ASCs with mucosal hom-
ing characteristics. This ﬁts with the concept that these ASCs were
derived from preexisting, mucosally generated MBCs re-activated
by IM administered antigen [35].
The frequencies of IgG + IgA ASCs speciﬁc for the GI.1 antigen and
for the GI.1 + GII.4 antigens correlated (p = 0.0040 and p = 0.0306,
respectively) with the frequencies of CD27+ CD38+ (CD19+ CD3−)
B cells (Fig. 4A and B). IgA ASCs speciﬁc for GI.1 (p = 0.0017) and
for GII.4 (p = 0.0114) also correlated with plasmablast frequen-
cies assessed by ﬂow cytometry. The stronger correlations of the
ﬂow cytometry data with the IgA secreting and GI.1-speciﬁc B cell
responses is very much in line with the overall bias to IgA and GI.1
depicted in Fig. 2E. ASC frequencies on day 7 have been correlated
with serum Ig titers on day 28 for inﬂuenza vaccines [28,36,37].
However norovirus VLP-speciﬁc serum antibody titers, measured
at any time point, and the ASC frequencies did not signiﬁcantly
correlate in the present study. The coincident rises in circulating
antibodies and ASC frequencies may  obscure a cause and effect rela-
tionship, even though changes in serum antibodies must certainly
follow activation of B cells to become ASCs.
Circulating frequencies of VLP-speciﬁc ASCs measured 7 days
after the second vaccination were substantially lower than after the
ﬁrst vaccination and serum titers of VLP-speciﬁc IgG, and IgA were
unchanged [30], consistent with a very low B cell response. This
result is somewhat surprising, since an expansion of VLP-speciﬁc
MBCs would be expected to accompany the vigorous ASC response
to the ﬁrst vaccination. However, the outcome of non-mucosal acti-
vation of IgA-expressing MBCs is unclear and it is possible that
the MBC  pool available to respond to antigen administered via
the same route could be transiently diminished. This could result
from newly formed IgA+ MBCs exiting the site of formation and
migrating through mucosa-associated tissues before homeostasis
is regained. The greater frequency of GI.1-speciﬁc IgG ASCs than
IgA ASCs after the second vaccination, in marked contrast to the
situation after the ﬁrst vaccination, may  also reﬂect a change in
the systemic availability of IgA+ MBCs. Another factor limiting the
response to the second vaccination may  have been the high levels
of circulating VLP-speciﬁc Abs induced by the ﬁrst vaccination [30].
Preexisting speciﬁc Abs are thought to increase the rate of clearance
of administered antigens and down-regulate immune responses.
In summary, we  demonstrate that an adjuvanted, bivalent
norovirus VLP vaccine elicits a vigorous, IgA-dominated ASC
A. Sundararajan et al. / Vaccine 33 (2015) 568–576 575
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